RECRUITING

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

Official Title

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Quick Facts

Study Start:2018-01-01
Study Completion:2027-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03452774

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Pts with solid and hematological malignancies;
  2. * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2/Neu, Tumor mutational burden/load (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A/B, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1/2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA/B/C, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.
  3. * Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and/or patient
  1. * ECOG PS \> 2;
  2. * Abnormal organ function;
  3. * Hospice enrollment

Contacts and Locations

Study Contact

Selin Kurnaz, PhD
CONTACT
+1(917) 336-3319
skurnaz@massivebio.com
Amanda Huttis, RN
CONTACT
+1(917) 336-3319
ahuttis@massivebio.com

Principal Investigator

Selin Kurnaz, PhD
PRINCIPAL_INVESTIGATOR
Massive Bio, Inc.

Study Locations (Sites)

Massive Bio, Inc
New York, New York, 10006
United States

Collaborators and Investigators

Sponsor: Massive Bio, Inc.

  • Selin Kurnaz, PhD, PRINCIPAL_INVESTIGATOR, Massive Bio, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-01-01
Study Completion Date2027-06

Study Record Updates

Study Start Date2018-01-01
Study Completion Date2027-06

Terms related to this study

Keywords Provided by Researchers

  • artificial intelligence
  • virtual tumor board
  • clinical trial
  • clinical trial matching
  • electronic medical record
  • machine learning
  • cost of care
  • targeted therapy
  • immunotherapy
  • precision medicine
  • precision oncology
  • cancer
  • value based care
  • real world data
  • data analytics

Additional Relevant MeSH Terms

  • Cancer, Metastatic
  • Cancer
  • Cancer of Pancreas
  • Cancer of Liver
  • Cancer of Stomach
  • Cancer Liver
  • Cancer of Rectum
  • Cancer of Kidney
  • Cancer of Esophagus
  • Cancer of Cervix
  • Cancer of Colon
  • Cancer of Larynx
  • Cancer, Lung
  • Cancer, Breast
  • Cancer, Advanced
  • Cancer Prostate
  • Cancer of Neck
  • Cancer of Skin
  • Neuroendocrine Tumors
  • Carcinoma
  • Mismatch Repair Deficiency
  • BRCA Gene Rearrangement
  • Non Hodgkin Lymphoma
  • Leukemia
  • Non Small Cell Lung Cancer
  • Cholangiocarcinoma
  • Glioblastoma
  • Central Nervous System Tumor
  • Melanoma
  • Urothelial Carcinoma
  • Bladder Cancer
  • Ovarian Cancer
  • Endometrial Cancer
  • Testicular Cancer
  • Breast Cancer
  • COVID
  • Myelofibrosis
  • Myeloproliferative Neoplasm
  • Myeloproliferative Disorders
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Marginal Zone Lymphoma
  • Myelodysplastic Syndromes